NVAX
Price
$8.63
Change
-$0.37 (-4.11%)
Updated
Dec 18, 04:59 PM (EDT)
76 days until earnings call
WXIBF
Price
$1.90
Change
-$0.60 (-24.00%)
Updated
Dec 17 closing price
Ad is loading...

NVAX vs WXIBF

Header iconNVAX vs WXIBF Comparison
Open Charts NVAX vs WXIBFBanner chart's image
Novavax
Price$8.63
Change-$0.37 (-4.11%)
Volume$62.12K
CapitalizationN/A
Wuxi Biologics Cayman
Price$1.90
Change-$0.60 (-24.00%)
Volume$8.25K
CapitalizationN/A
NVAX vs WXIBF Comparison Chart
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WXIBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVAX vs. WXIBF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and WXIBF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (NVAX: $9.00 vs. WXIBF: $1.90)
Brand notoriety: NVAX: Notable vs. WXIBF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 51% vs. WXIBF: 10%
Market capitalization -- NVAX: $1.44B vs. WXIBF: $8.89B
NVAX [@Biotechnology] is valued at $1.44B. WXIBF’s [@Biotechnology] market capitalization is $8.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileWXIBF’s FA Score has 1 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • WXIBF’s FA Score: 1 green, 4 red.
According to our system of comparison, WXIBF is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while WXIBF’s TA Score has 4 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • WXIBF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than WXIBF.

Price Growth

NVAX (@Biotechnology) experienced а +2.62% price change this week, while WXIBF (@Biotechnology) price change was -24.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

NVAX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WXIBF($8.89B) has a higher market cap than NVAX($1.44B). NVAX YTD gains are higher at: 87.500 vs. WXIBF (-48.787). WXIBF has higher annual earnings (EBITDA): 5.5B vs. NVAX (-216.36M). WXIBF has higher revenues than NVAX: WXIBF (17B) vs NVAX (847M).
NVAXWXIBFNVAX / WXIBF
Capitalization1.44B8.89B16%
EBITDA-216.36M5.5B-4%
Gain YTD87.500-48.787-179%
P/E RatioN/A23.07-
Revenue847M17B5%
Total Cash910MN/A-
Total Debt233MN/A-
FUNDAMENTALS RATINGS
NVAX vs WXIBF: Fundamental Ratings
NVAX
WXIBF
OUTLOOK RATING
1..100
1841
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
10044
PRICE GROWTH RATING
1..100
4836
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WXIBF's Valuation (65) in the null industry is in the same range as NVAX (87) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as WXIBF (100) in the null industry. This means that NVAX’s stock grew similarly to WXIBF’s over the last 12 months.

WXIBF's SMR Rating (44) in the null industry is somewhat better than the same rating for NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew somewhat faster than NVAX’s over the last 12 months.

WXIBF's Price Growth Rating (36) in the null industry is in the same range as NVAX (48) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's P/E Growth Rating (20) in the null industry is significantly better than the same rating for NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew significantly faster than NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXWXIBF
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WXIBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSUIX23.11-0.10
-0.43%
Cohen & Steers Global Infrastructure I
FKGRX149.68-0.76
-0.51%
Franklin Growth A
AAUTX29.57-0.20
-0.67%
Thrivent Large Cap Value A
LBGAX44.42-0.48
-1.07%
ClearBridge Mid Cap Growth A
WWSCX17.58-0.25
-1.40%
TETON Westwood SmallCap Equity C

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with THRD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then THRD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.49%
THRD - NVAX
42%
Loosely correlated
+2.07%
ITOS - NVAX
39%
Loosely correlated
-1.03%
ADMA - NVAX
35%
Loosely correlated
-1.84%
PGEN - NVAX
33%
Loosely correlated
+2.46%
RXRX - NVAX
33%
Loosely correlated
-4.30%
More

WXIBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, WXIBF has been loosely correlated with WXXWY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if WXIBF jumps, then WXXWY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WXIBF
1D Price
Change %
WXIBF100%
-24.00%
WXXWY - WXIBF
46%
Loosely correlated
-0.99%
JAGX - WXIBF
22%
Poorly correlated
+2.62%
NVAX - WXIBF
21%
Poorly correlated
-2.49%
ELVAF - WXIBF
21%
Poorly correlated
N/A
EVAX - WXIBF
20%
Poorly correlated
-8.92%
More